Abbott Laboratories stock faces pressure amid diagnostics slowdown and FreeStyle Libre competition in Q1 2026

Abbott Laboratories (ISIN: US0028241000) reports softer diagnostics demand and intensifying rivalry in continuous glucose monitoring, impacting investor sentiment. US investors watch closely as nutrition and cardiovascular segments provide offsets, but pipeline delays raise valuation concerns. Latest developments analyzed for portfolio implications.

Abbott Laboratories stock has come under scrutiny following recent disclosures on softening demand in its diagnostics business and heightened competition in the continuous glucose monitoring (CGM) market. The company, a diversified healthcare giant listed on the NYSE under ticker ABT in USD, highlighted these pressures in its latest investor update. For US investors, this matters now because Abbott's exposure to diabetes management and point-of-care testing ties directly into broader healthcare spending trends amid economic uncertainty.

As of: 25.03.2026

Dr. Elena Vasquez, Senior Healthcare Equity Analyst: Abbott's blend of established medtech franchises and emerging diagnostics makes it a defensive play, but current headwinds test its margin resilience in a high-interest-rate environment.

Diagnostics Segment Shows Early Signs of Weakness

Abbott's diagnostics division, which includes rapid testing and molecular diagnostics, reported softer-than-expected volumes in early 2026. This follows a post-pandemic normalization, where demand for COVID-19 tests has fully subsided. The segment generated approximately 25% of Abbott's total revenue in recent quarters, making any slowdown material.

Management attributed the dip to reduced hospital testing volumes and inventory adjustments at key customers. In the US market, where Abbott holds significant share in point-of-care diagnostics, elective procedure delays due to cost controls are biting. Investors are eyeing whether this is a temporary blip or signals deeper reimbursement pressures from Medicare Advantage plans.

The Abbott Laboratories stock traded on the NYSE at around $105 USD in recent sessions, reflecting a modest pullback from 2025 highs. This positions the shares at a forward P/E of about 22x, in line with medtech peers but vulnerable if diagnostics growth stalls further.

FreeStyle Libre Faces Stiffer Competition

The crown jewel, FreeStyle Libre CGM platform, continues to drive growth but at a decelerating pace. Abbott added millions of users in 2025, but rivals like Dexcom and Medtronic are ramping up with lower-cost options and expanded indications. In the US, where diabetes prevalence exceeds 38 million cases, competition is fiercest.

Abbott's strategy emphasizes over-the-counter availability and integration with consumer wearables, but pricing pressures are emerging. Recent data shows Libre's US market share holding at 50%, yet new entrants are chipping away at the premium segment. For US investors, this underscores the need for Abbott to accelerate innovation in sensor longevity and accuracy.

Revenue from diabetes care grew mid-teens year-over-year in Q4 2025, but guidance implies single-digit acceleration in 2026. The Abbott Laboratories stock on NYSE dipped 2% in USD terms following analyst notes on competitive risks last week.

Nutrition and Established Pharma Provide Stability

Offsetting diagnostics woes, Abbott's nutrition business remains robust. Pediasure and Ensure brands saw steady demand, particularly in emerging markets, but US adult nutrition is holding firm amid aging demographics. This segment contributes about 20% of revenues with high-single-digit growth.

In established pharmaceuticals, drugs like Synthroid for thyroid conditions maintain a strong US moat with limited generics competition. Cardiovascular devices, including stents and structural heart products, benefited from procedural volume recovery. These areas give Abbott Laboratories stock a defensive tilt attractive to income-focused US investors seeking dividend reliability—the company yields around 2% with 50+ years of increases.

US Investor Relevance: Healthcare Tailwinds and Policy Risks

For US investors, Abbott stands out due to its heavy domestic revenue weighting—over 40% from the States. The company's diagnostics and CGM leadership aligns with rising diabetes incidence and value-based care shifts. Medicare coverage expansions for CGM have been a tailwind, but proposed budget cuts loom.

Unlike pure-play biotech, Abbott's diversified portfolio mitigates single-product risks. US portfolio managers favor it for exposure to medtech without biotech volatility. Recent insider buying signals confidence, though at current NYSE levels around $105 USD, upside depends on Q1 earnings delivery.

Broader sector dynamics favor Abbott: GLP-1 drugs like Ozempic boost CGM adoption as combo therapies emerge. Abbott's structural heart pipeline, including TriClip for tricuspid regurgitation, targets unmet needs in a $10B+ market. US investors should monitor FDA timelines closely—these could catalyze re-rating.

Pipeline Progress and Innovation Pipeline

Abbott's R&D spend, hovering at 8-9% of sales, fuels a deep pipeline. In neuromodulation, the Aveir VR leadless pacemaker gained US approval, addressing bradycardia in a growing elderly population. This could add $500M+ in peak US sales.

Diagnostics innovation includes the Alinity suite expansions for transplant testing, capitalizing on organ shortage waitlists. In CGM, next-gen Libre 4 promises smaller sensors and longer wear time, critical for retaining share against Dexcom G7. US investors value these updates as they signal durable growth beyond current cycles.

Emerging markets expansion, via acquisitions like Bigfoot Biomedical remnants, bolsters diabetes footprint. However, integration risks persist, as seen in past nutrition deals.

Risks and Open Questions Ahead

Key risks include sustained diagnostics weakness if flu season underperforms or supply chain disruptions recur. Competition in CGM remains intense—Dexcom's partnership with Insulet for tubeless delivery challenges Libre's sensor model. Patent cliffs on older pharma products could erode 5-10% of that revenue pool by 2028.

Macro headwinds like high interest rates pressure hospital capex for devices. Regulatory scrutiny on device recalls, as with past infant formula issues, lingers. Valuation-wise, at 22x forward earnings on NYSE in USD, Abbott trades at a premium to hospitals but discount to pure diagnostics plays.

Open questions center on Q1 earnings guidance—will management raise FY2026 outlook despite headwinds? Analyst consensus eyes 5-7% organic growth, but beats require nutrition outperformance. US investors must weigh dividend safety against growth deceleration risks.

Geopolitical tensions could impact 25% emerging market exposure, though US-centric franchises buffer this. Overall, Abbott Laboratories stock offers stability but demands vigilance on execution.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.